Overview

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma

Status:
Not yet recruiting
Trial end date:
2024-08-15
Target enrollment:
Participant gender:
Summary
This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.
Phase:
Phase 1
Details
Lead Sponsor:
Oblato, Inc.